Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Aldeyra Therapeutics, Inc. < Previous 1 2 Next > Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable June 20, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease June 13, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics to Host Investor Roundtable Q&A June 12, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference May 29, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease May 08, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day April 25, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 April 18, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease March 28, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 06, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases January 04, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis December 19, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis December 18, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease November 27, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap November 01, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum July 06, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa June 29, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa June 28, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough June 27, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough June 26, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis June 14, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference June 02, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights May 04, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis April 13, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis April 06, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough March 30, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa March 16, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights March 09, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma March 02, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights March 01, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease February 28, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Tickers ALDX < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.